350 rub
Journal Technologies of Living Systems №4 for 2014 г.
Article in number:
Transfer factor as a component of esophageal cancer treatment
Keywords: cancer tumor esophagus immunity immunotherapy peptides transfer factors comprehensive treatment treatment strategy
Authors:
S.K. Pinaev - Ph.D. (Med.), Russian Academy of Sciences, Far Eastern branch, Computer Center (Khabarovsk, Russia). E-mail: pinaev@mail.ru
O.G. Pinaeva - Teacher, Department of Pathological Physiology, Far Eastern State Medical University (Khabarovsk, Russia). E-mail: pinaeva_og@mail.ru
A.Ya. Chizhov - Dr.Sc. (Med.), Professor, Peoples' Friendship University of Russia (Moscow, Russia). E-mail: ma21@mail.ru
Abstract:
Esophageal cancer refers to tumors with a poor prognosis. This is due to the anatomical localization of the tumor, its low sensitivity to radiotherapy and chemotherapy, and a high frequency of comorbidity. The existing situation requires the development of new effective treatments for cancer of the esophagus. One promising area is the immunotherapy of tumors with Transfer factor - (TF). The authors describe two cases of treatment esophageal cancer using TF. In first case, a patient with cancer of the lower esophagus (T1-2N0M0) due to severe comorbidities were refused special treatment. He was treated with transfer factor only. After two months of treatment was achieved complete tumor regression. It was confirmed by esophagoscopy. In the following 4 months was found local tumor progression without distant metastasis. Survival was 26 months from diagnosis. Another patient with cancer of the lower esophagus (T1N0M0) had TF therapy on a background of teletherapy. After two months achieved complete tumor regression confirmed esophagoscopy. The patient is in stable remission at the moment. He is under the dynamic supervision by esophagoscopy. Conclusions about the pronounced therapeutic effect of TF in esophageal cancer, comparable with chemoradiotherapy. In this combination of immunotherapy by TF and radiotherapy has synergies and allows for complete regression of tumors of the esophagus. Suggested when the regression "incurable" cancer of the esophagus on the background of preparations TF back to the question about the possibility of special treatment. Also made proposals to expand these studies to obtain representative data on place and importance of of TF in the complex treatment of esophageal cancer.
Pages: 59-62
References

  1. Bisenkov L.N., Roman L.D., Kotiv B.N. i dr. Palliativny'e vmeshatel'stva v xirurgicheskom lechenii raka grudnogo otdela pishhevoda // Voprosy' onkologii. 2009. № 1. S. 56-59.
  2. Gastinger I., Klyuge Yo., Kube R. i dr. Xirurgicheskoe lechenie zlokachestvenny'x novoobrazovanij pishhevoda // Xirurgiya. 2009. № 9. S. 50-54.
  3. Gladkov O.A., Vazhenin A.V., Sharabura T.M. i dr. Sravnenie e'ffektivnosti neoad''yuvantnogo ximioluchevogo lecheniya v sravnenii s predoperaczionnoj luchevoj terapiej pri rake grudnogo otdela pishhevoda // Palliativnaya mediczina i reabilitacziya. 2009. № 1. S. 18-21.
  4. Grіnevich Ju.Ja., Fіl'chakov F.V., Shumіlіna K.S., Bobro L.І., L'on G.D. Faktor perenosu: otrimannya ta protipuxlinnі vlastivostі // Zhurnal akademії medichnix nauk ukraїni. 2008. T. 14. № 4. S. 617-635.
  5. Immunoreabilitacziya pri infekczionno-vospalitel'ny'x i somaticheskix zabolevaniyax s ispol'zovaniem Transfer Faktorov: Metodicheskoe pis'mo. M.: Ministerstvo zdravooxraneniya i soczial'nogo razvitiya Rossijskoj Federaczii. 2004. 34 s.
  6. Oganova E'.A., MakKosland V. Kelvin. Transfer Faktory' ? prirodny'e immunokorrektory' // V sb. nauch.-prakt konf. s mezhdunar. uchastiem: «Immunoreabilitacziya pri infekczionno-vospalitel'ny'x zabolevaniyax». g. Barnaul. 29 noyabrya 2003. S. 22-26.
  7. Sidorenko Ju.S., Kasatkin V.F., Grushko A.S. Ad''yuvantnaya autogemoximioterapiya v kompleksnom lechenii bol'ny'x rakom grudnogo otdela pishhevoda // Palliativnaya mediczina i reabilitacziya. 2009. № 2. S. 29-31.
  8. Forghanifard M.M., Gholamin M., Farshchian M. et al. Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy // Cancer Biology & Therapy. 2011. V. 12. № 3. P. 191-197.
  9. Lobuglio A.F., Neidhart A.J. A review of Transfer Factor immunotherapy in cancer // Cancer. 1974. V. 34. P. 1563-1570.
  10. Pizza C., De Vinci C., Fudenberg H.H. Transfer factor in Malignancy // Progress in Drug Res. 1994. V. 42. P. 401-421.
  11. Schwarz M.A., Gutterman J.U., Burgess M. A. et al. Chemoimmunotherapy of Disseminated Malignant Melanoma with OTIC-BCG, Transfer Factor + Melphalan // Cancer. 1980. V. 45. P. 2506-2515.
  12. Ueda Y., Yamagishi H., Tanioka Y. et al. Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer // Hepatogastroenterology. 1999. May. V. 46. Suppl. 1. P. 1274-1279.